Ryman Healthcare managing director Simon Challies. Photo: Natalie Slade.
Ryman Healthcare managing director Simon Challies. Photo: Natalie Slade.
Ryman Healthcare has posted another record full-year profit, rounding out 14 straight years of earnings growth as New Zealand's largest retirement village operator ramped up its Australian expansion and increased re-sales of occupation rights.
Underlying profit, which excludes fair value changes from its property portfolio, rose 16 percent to $157.7million in the 12 months ended March 31, the Christchurch-based company said in a statement. Operating revenue climbed 15 percent to $261 million.
Net profit, which included about $152 million of unrealised revaluations of units on the back of new stock and a strong housing market, jumped 26 percent to $305 million.
Ryman's business model, which taps into New Zealand's ageing demographic and demand for quality retirement options, is so successful that it has become an industry benchmark, emulated by rivals including Summerset Group.
The company hasn't sought fresh capital from shareholders since its 1999 initial public offering raised $25 million, yet has invested $2.1 billion expanding its villages since then while returning $500 million in dividends.
The company had its busiest building programme on record in 2016, and while it is projecting a quieter 2017, its expansion plans are projected to surge again between 2018 and 2021, mainly driven by activity in Australia. It currently has five new villages under construction, three awaiting consent and four planned, adding to its existing 30 villages.
Operating cash flow surged 34 percent to $312 million in a year when growth was driven by record levels of demand and a buoyant housing market, chairman David Kerr said.
"Looking out past 2020, our long-term plan is to match our New Zealand build rate in Australia," Kerr said. "We are excited about the opportunity that both markets offer."
Ryman will pay a final dividend of 8.5 cents a share, up from 7.3 cents a year earlier and lifting payments for the full year by 16 percent.
Ryman's shares last traded at $9.60 and have gained about 13 percent this year, outpacing the S&P/NZX 50 Index's 9.2 percent gain. Over the past five years, the stock has shot up 258 percent while the benchmark index gained 93 percent. It is rated a 'hold' based on the consensus of five analysts surveyed by Reuters.
